Atopic Dermatitis Clinical Trials in New York, New York

12 studies are recruiting for atopic dermatitis in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

   The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Atd002 52022, New York, New York

   Locations

   68 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT07277660 on ClinicalTrials.gov

2. A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

   This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Investigational Site, New York, New York

   Locations

   71 in total

   Run by

   Apogee Therapeutics, Inc.

   See if you can join NCT07003425 on ClinicalTrials.gov

3. Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis

   Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients. The investigators hypothesi…

   Stage

   Not phased

   Ages

   13 to 17

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   2 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT07746427 on ClinicalTrials.gov

4. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Sadick Research Group, LLC, New York, New York

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

5. A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

   This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

   Stage

   Phase 1

   Ages

   18 to 72

   Site

   OptiSkin Medical, New York, New York

   Locations

   14 in total

   Run by

   Bambusa Therapeutics

   See if you can join NCT06808477 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

   The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

   Stage

   Phase 2

   Ages

   18 to 74

   Site

   Inmagene Site 21, New York, New York

   Locations

   30 in total

   Run by

   Inmagene LLC

   See if you can join NCT07037901 on ClinicalTrials.gov

7. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy an…

   Stage

   Phase 3

   Ages

   18 to 63

   Site

   Equity Medical /ID# 265814, New York, New York

   Locations

   128 in total

   Run by

   AbbVie

   See if you can join NCT06389136 on ClinicalTrials.gov

8. Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

   This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and pediatric participants with atopic…

   Stage

   Phase 1

   Ages

   6 and older

   Site

   Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology, New York, New York

   Locations

   8 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06504160 on ClinicalTrials.gov

9. A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

   The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Private Practice - Dr. Bobby Buka, New York, New York

   Locations

   98 in total

   Run by

   Pfizer

   See if you can join NCT05995964 on ClinicalTrials.gov

10. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

    The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

    Stage

    Not phased

    Ages

    12 and older

    Site

    Galderma Investigational Site - 7051, New York, New York

    Locations

    108 in total

    Run by

    Galderma R&D

    See if you can join NCT06988605 on ClinicalTrials.gov

11. Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

    This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achievi…

    Stage

    Phase 2

    Ages

    12 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT07242638 on ClinicalTrials.gov

12. A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

    The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: * Are currently or recently pregnant * Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR…

    Stage

    Not phased

    Ages

    0 and older

    Site

    Pfizer, New York, New York

    Run by

    Pfizer

    See if you can join NCT05721937 on ClinicalTrials.gov